As of 10:32 AM on the 16th, SK is trading at 309,500 KRW, up 1.81% from the previous day. The trading volume is 1,001,517 shares, which is about 23.39% of the previous day's volume. SK is known as the holding company of the SK Group.

On June 11, Choi Jung-wook, a researcher at Hana Financial Investment, stated, "The investment points are 1) a portfolio mix and expansion with clear principles and philosophy, 2) high potential for corporate value increase through the lineup of unlisted subsidiaries, and 3) additional NAV expansion expectations upon the transfer of SK Hynix subsidiaries currently submerged. Following SK Biopharm, the IPO momentum continuing with SK Siltron and SK Pharmteco is also expected to be highlighted. Despite some subsidiaries’ profit declines, the annual cash flow flowing into the holding company is expected to increase, raising dividend expectations." He set SK’s target price at 320,000 KRW.

Over the past five days, individual investors have net purchased 401,203 shares of SK, while foreigners and institutions have net sold 306,830 shares and 75,737 shares, respectively.

※Source: AI Investment Assistant AI Rassiro

※ This article was generated in real-time by an automated article creation algorithm jointly developed by Asia Economy and financial AI specialist Thinkpool.




This content was produced with the assistance of AI translation services.

© The Asia Business Daily(www.asiae.co.kr). All rights reserved.

Today’s Briefing